Cardiol Therapeutics Inc (CRDL) News

NASDAQ: $CRDL is advancing CardiolRx™ for acute myocarditis and recurrent pericarditis, both in Phase II trials. The company raised $13.5 million

NASDAQ: $CRDL A target of $10 per share (approximately C$13.60) is proposed, indicating a potential upside of over 5x within a year, contingent on strong data readouts for CardiolRx™?

Cardiol Therapeutics sets a 12-month price target of $10, valuing CardiolRx at $9 for recurrent pericarditis and $1 for acute myocarditis, based on projected sales and associated probabilities.

$CRDL Insider Buying: Cardiol CEO David Elsley purchased approximately $100,000 in shares at about $2.03 each

NASDAQ: $CRDL Cardiol Therapeutics sets a 12-month price target of $10, valuing CardiolRx at $9 for recurrent pericarditis and $1 for acute myocarditis, based on projected sales and associated probabilities

NASDAQ: $CRDL 12-month price target is $10, with $9 attributed to recurrent pericarditis and $1 to acute myocarditis

NASDAQ: $CRDL is advancing CardiolRx for acute myocarditis and recurrent pericarditis, both in Phase II trials. The company raised $13.5 million

Cardiol sets a 12-month price target of $10

NASDAQ: $CRDL Short Squeeze Allerts 

A target of $10 per share (approximately C$13.60) is proposed, indicating a potential upside of over 5x within a year, contingent on strong data readouts for CardiolRx™?

Volume looks GOOD 💃💃🚀

NASDAQ: $CRDL Valuation: The 12-month price target is $10, with $9 attributed to recurrent pericarditis and $1 to acute myocarditis

PICK UP $CRDL THIS MORNING

NASDAQ: $CRDL H.C. Wainwright maintains a "Buy" rating for Cardiol Therapeutics (CRDL) with a price target of $9.00.

CardiolRx could serve as an earlier treatment alternative, competing with Arcalyst, which costs $300,000 annually.

Cardiol Therapeutics recently reported encouraging outcomes from its Phase II MAvERIC trial of CardiolRx, an ultra-pure oral cannabidiol formulation for recurrent pericarditis. Key highlights include:

Pain Reduction: Average pain intensity decreased significantly from 5.8 to 2.1 on an 11-point scale after eight weeks.
C-Reactive Protein (CRP) Levels: Marked reduction in inflammation, comparable to Kiniksa’s rilonacept from the Phase III RHAPSODY trial.

$CRDL CEO Investment: Cardiol CEO David Elsley purchased approximately $100,000 in shares at about $2.03 each, indicating strong personal conviction in the company's potential.

$CRDL Financial Strategy: With about $21 million in cash, the company may consider a small capital raise if new data boosts the stock price, aiming for a target of $10 per share (C$13.60

ARCHER trial (acute myocarditis) completed enrollment, with results expected in Q1 2025. Orphan status could lead to $120M peak sales.

NASDAQ: $CRDL Promising clinical progress: Ongoing Phase II trials for myocarditis and pericarditis, with major data expected November 2024

Time to Add $CRDL Big wave coming

NASDAQ: $CRDL is advancing CardiolRx for acute myocarditis and recurrent pericarditis, both in Phase II trials. The company raised $13.5 million, with key trial results due in November 2024?

NASDAQ: $CRDL is advancing CardiolRx for acute myocarditis and recurrent pericarditis, both in Phase II trials. The company raised $13.5 million, with key trial results due in November 2024?

Cardiol Therapeutics (NASDAQ: CRDL) is starting the MAVERIC-2 trial to test CardiolRx™ for recurrent pericarditis, targeting patients discontinuing IL-1 blocker therapy. Positive earlier trial results will be presented in November 2024

CRDL under $2

Cardiol Therapeutics Inc. ($CRDL) is a clinical-stage life sciences company specializing in anti-inflammatory and anti-fibrotic therapies for heart disease. Its lead candidate, CardiolRx™ (cannabidiol), is in clinical development with a 52-week trading range of $0.661 to $3.12.

CRDL under $3

CRDL grabbed some July19 2.50 calls at a nickel, lotto play, chart looking better…

Good!

Higher lows...still bullish

I like!

>$4 likely

Back to $3?

There's volume...looks like run will continue

Yeah...we need to keep plenty of rainy day cash in the jar lol

Tough week, no doubt

My portfolio is in a depression at the moment...may have to eat dirt ala mode for dinner tonight

There will not be one until after they submit which wu probably be around $1-$1.50 area

RGDL too high too fast...will wait on pullback

Will look at it...watch CDRL go lower now that I text you...I bet I jinxed it lol

Nice. $RDGL about to go up big time!

Morning...there are signs this is stablizing...both my CRDL and WMT calls are green this morning

Im finding more and more playing options
are the way to go if careful

No doubt

...all depends which way the wind blows

It looks excessive but wouldn’t be surprised to see the $1-1.50 range after it run up with $2 being the area it settles in before its first leg up following this downturn

Im thinking they're diluting because they need money for phase 3 trial...otherwise I dont know why the huge sell off

1.50 could be bottom but 1.75 more likely

$1 bid here if my $1.50’s get filled

Nice

I got em...bought 10

Agreed

Nah...it only allows .05 increments...bidding .15...dont want to bid .20...if doesnt fill will let it go and buy something else...tomorrow is a stock mkt holiday and its summer so a weak mkt is expected

Gm- u get filled?

GM... bidding 6/19 2.50 calls @.15

I’m adding about 500-1k a day for the next couple of weeks